Drug giant Pfizer is close to signing a $14bn agreement to acquire biotech firm Medivation.
Pfizer has been seeking acquisitions as the sales of its older drugs have slowed down, reported Bloomberg.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The two firms are in the process of finalising the deal, which could be announced today, reported the Financial Times, citing sources familiar with the matter.
Pfizer has a market valuation of $212bn and intends to acquire Medivation by paying a premium of about one-third to latter's closing price of $67.16 per share last Friday. This would raise the value of Medivation's equity to more than $14bn.
The deal will put an end to months of bidding for Medivation.
Celgene, Gilead and Sanofi were the other firms in the race to acquire San Francisco-based Medivation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMedivation manufactures prostate cancer drug Xtandi, which is expected to generate annual revenues of $5.7bn by 2020.
Furthermore, the biotech firm, which was established in 2004, is developing a drug called Talazoparib that is aimed at stopping tumour cells from multiplying.
Sanofi had provided a $9.3bn offer to Medivation at the end of April.
Pfizer attempted to acquire Ireland-based Allergan for $150bn, but this attempt was stopped by the US administration as the firm intended to shift its headquarters to Ireland due to low-tax policy.
